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ABSTRACTS
The E3 ligase HERC4 is overexpressed in human breast
cancer and its expression levels correlated with the
prognosis of breast cancer patients. However, the roles
of HERC4 in mammary tumorigenesis remain unclear.
Here we demonstrate that the knockdown of HERC4 in
human breast cancer cells dramatically suppressed
their proliferation, survival, migration, and tumor growth
in vivo, while the overexpression of HERC4 promoted
their aggressive tumorigenic activities. HERC4 is a new
E3 ligase for the tumor suppressor LATS1 and destabi-
lizes LATS1 by promoting the ubiquitination of LATS1.
miRNA-136-5p and miRNA-1285-5p, expression of which
is decreased in human breast cancers and is inversely
correlated with the prognosis of breast cancer patients,
are directly involved in suppressing the expression of
HERC4. In summary, we discover a miRNA-HERC4-
LATS1 pathway that plays important roles in the patho-
genesis of breast cancer and represents new therapeu-
tic targets for human breast cancer.
KEYWORDS E3 ligase, tumorigenesis, ubiquitination,
tumor suppressor, miRNA
INTRODUCTION
Breast cancer is one of the most deadly cancers worldwide
with increasing frequency and mortality rates (Dubey et al.,
2015). The mammary tumorigenesis is a multistep process
involving various genetic and epigenetic alterations, leading
to the activation of various oncoproteins or inactivation of
tumor suppressors (Duffy et al., 2000; Weidle et al., 2018).
For example, several oncogenic receptors such as estrogen
receptor (ER), progesterone receptor (PR) and human epi-
dermal growth factor type 2 receptor (HER2), have been
identified as the key regulators of mammary tumorigenesis
(Patani et al., 2013; Mayer et al., 2017). Due to its genetic
and epigenetic heterogeneity, breast cancers of advanced
stages remain very difficult to treat. Therefore, it is critical to
elucidate the pathways that drive breast tumorigenesis to
identify new and more effective therapeutic targets.
The Hippo pathway plays critical roles in controlling the
organ and tissue homeostasis by modulating cellular prolif-
eration and apoptosis, and is deregulated in various human
cancers (Pfleger, 2017). The Hippo pathway is a tumor
suppressor pathway consisting of multiple proteins, including
MST1/2, MOB1 and large tumor suppressor 1/2 (LATS1/2)
(Furth and Aylon, 2017; Kulaberoglu et al., 2017). LATS1/2
kinases phosphorylate YAP and TAZ to inactivate these
oncogenic proteins (Furth and Aylon, 2017). In addition,
LATS kinases can suppress breast cancer by promoting the
ubiquitination and degradation of ERα as well as inhibiting
the differentiation of bipotent luminal progenitors, a proposed
cellular origin of human breast cancers (Britschgi et al.,
2017).
Ubiquitin-proteasome system (UPS) regulates the
dynamic change of protein levels of intracellular proteins
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(Hershko, 2005) and plays important roles in cancer devel-
opment (Micel et al., 2013; Mofers et al., 2017). The six
members of the HERC family proteins contain both HECT
and RCC-1-like domains (Mitsui et al., 1999). The HECT
domain can function as a ubiquitin/ubiquitin-like (UBL) pro-
tein ligase by ligating polyubiquitin chains to proteins for
recognition and degradation via the proteasome (Rotin and
Kumar, 2009). Accumulating data demonstrate that HERC
family proteins are functionally linked to malignant tumor
development. For example, HERC1, the first identified
member of the HERC family protein, is a key E3 ligase of
MutS homolog 2 (MSH2), a DNA mismatch repair enzyme
that plays a pivotal role in maintaining genomic integrity
(Diouf et al., 2011). The expression levels of HERC2, which
is involved in DNA double-strand break (DSB) repair, are
positively correlated with the poor prognosis of non-small-
cell lung cancer (Bonanno et al., 2016).
Another member of the HERC family proteins, HERC4,
plays important roles in spermatogenesis and male fertility
(Rodriguez and Stewart, 2007). HERC4 is overexpressed in
several types of cancer such as lung cancer and hepato-
cellular carcinoma (Zeng et al., 2015; Zheng et al., 2017).
The overexpression of HERC4 is correlated with the poor
prognosis of breast cancer patients (Zhou et al., 2013). Here
we demonstrate that HERC4 promotes breast cancer pro-
gression by destabilizing tumor suppressor LATS1. In addi-
tion, we identified the upstream tumor suppressive miRNAs
that suppress breast tumorigenesis by inhibiting the
expression of HERC4 in human breast cancer cells.
RESULTS
HERC4 promoted tumorigenesis of breast cancer cells
Using the expression data of HERC4 in breast tumors and
tumor-adjacent normal tissues in the database (GSE 93601),
we confirmed that HERC4 was overexpressed in breast
cancers (Fig. 1A, top panel). In addition, the expression
levels of HERC4 were inversely correlated with the prog-
nosis of human breast cancer patients (Fig. 1A, bottom
panel). These data support the notion that HERC4 promotes
breast tumorigenesis. To investigate the roles of HERC4 in
breast tumorigenesis, we examined the expression levels of
HERC4 mRNA and protein in various breast cancer cell
lines. When compared to the normal breast epithelial cell line
MCF-10A, the expression levels of HERC4 mRNA and
protein were increased in breast cancer cell lines such as
MDA-MB-231 and MCF-7 cells (Fig. S1A and S1B). There-
fore, we examined the roles of HERC4 in these breast
cancer cells by knockdown or overexpression of HERC4
(Fig. S1C–F). The silencing of HERC4 decreased the cel-
lular proliferation and survival of MCF-7 cells (Fig. 1B). Using
transwell assays, we further showed that the silencing of
HERC4 inhibited the migration of MCF7 cells (Fig. 1C).
These data indicate that HERC4 promotes various aspects
of tumorigenesis of breast cancer cells. Consistent with this
conclusion, the overexpression of HERC4 in MCF7 cells
promoted the proliferation, migration and survival of MCF7
cells (Fig. 1D–F). In further support of an important role of
HERC4 in the tumorigenesis of breast cancer cells, the
knockdown of HERC4 in MCF7 cells significantly reduced
the growth of tumors formed by MCF7 cells in immunodefi-
cient mice (Fig. 1G). Consistent data were obtained using
another breast cancer cell line MDA-MB-231 cells (Fig. S2).
Since HERC4 is also frequently overexpressed in human
lung cancers, we also studied the roles of HERC4 in human
lung cancer cell line A549. The knockdown of HERC4 in
A549 lung cancer cells also suppressed their cellular prolif-
eration, migration and survival (Fig. S3). These findings
demonstrate that HERC4 is important for promoting
tumorigenesis.
HERC4 destabilizes tumor suppressor LATS1
As an E3 ligase, we predicted that HERC4 likely functioned
by regulating the stability of other proteins involved in
tumorigenesis. Therefore, to understand the mechanisms
how HERC4 promotes breast tumorigenesis, we used
STRING Protein-Protein Interaction database to predict the
proteins that might interact with HERC4 (Fig. 2A). One
identified candidate was the tumor suppressor LATS1 known
to suppress breast tumorigenesis. Using co-immunoprecipi-
tation (CO-IP) assay, we confirmed the interaction between
HERC4 and LATS1 in breast cancer cells (Fig. 2B). In
addition, the protein levels of HERC4 were inversely corre-
lated with the protein levels of LATS1 in breast cancer cells,
supporting the notion that HERC4 negatively regulates the
protein levels of LATS1 (Fig. 2C).
To test whether HERC4 can destabilize LATS1, the
overexpression of HERC4 significantly reduced the half-life
of LATS1 in both normal breast epithelial cells and breast
cancer cells, indicating that HERC4 destabilizes LATS1
(Fig. 3A). In support of the hypothesis that HERC4 could
b Figure 3. HERC4 destabilized tumor suppressor LATS1.
(A) The overexpression of HERC4 (HERC4 oe) in MCF-7
breast cancer cells and MCF-10A normal mammary epithelial
cells reduced the stability of LATS1. (B) The protein levels of
HERC4 were inversely correlated with the ubiquitination levels
of LATS1. The HA tagged ubiquitin was expressed in 293 cells
with overexpression (oe) or knockdown (si) of HERC4. LATS1
was immunoprecipitated and its ubiquitination levels deter-
mined with anti-HA antibody (top panel). As an internal control,
the protein levels in the input were determined by Western blot
(bottom panel). (C) HERC4 was bound to the C-terminus of the
LATS1 (left panel). HERC4 was co-expressed with GST-LATS1
or GST-LATS1 deletion mutants, and their interaction verified by
GST pull-down assay (left panel). K860R and K1005R mutants
of GST-LATS1 failed to pull down HERC4 (right panel). (D) The
overexpression of HERC4 partially rescued the proliferative
defects induced by LATS1 overexpression. n = 3. *P < 0.05,
**P < 0.01.
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serve as an E3 ligase for LATS1, the overexpression of
HERC4 increased the ubiquitination of LATS1 and the
knockdown of HERC4 reduced the ubiquitination of LATS1
(Fig. 3B). To identify the region of LATS1 that is involved in
interacting with HERC4, we examined the interaction
between HERC4 and the three deletion mutants of LATS1,
and found that HERC4 interacted with the C-terminus (aa
701–1,130) of LATS1 that contained two putative ubiquiti-
nation sites K860 and K1005 (Fig. 3C). The overexpression
of LATS1 reversed the tumorigenic activities induced by the
overexpression of HERC4 in breast cancer cells (Fig. 3D).
Therefore, HERC4 promotes the breast tumorigenesis by
destabilizing LATS1.
miR-1285-3p and miR-136-5p negatively regulate
the expression of HERC4
miRNA plays important roles in tumor suppression or onco-
genesis (Campos-Parra et al., 2017; Rupaimoole and Slack,
2017). Considering the importance of HERC4 in promoting
breast tumorigenesis, we used miRDB prediction program
(http://www.mirdb.org/cgi-bin/search.cgi) and GEO datasets
(GSE42072) to predict miRNAs that might target HERC4
mRNA. Based on the predicted results, two miRNAs, miR-
1285-3p and miR-136-5p, were identified as potential regu-
lators of HERC4a mRNA. Consistent with previous findings
that miR-136 was downregulated in triple negative breast
cancers (Yan et al., 2016), we found that the expression
levels of miR-1285-3p and miR-136-5p were higher in tumor-
adjacent normal tissues than in breast tumor tissues
(Fig. S4B). In addition, the expression levels of miR-1285-3p
and miR-136-5p in breast cancers were inversely correlated
with the prognosis of breast cancer patients (Fig. 4A).
To determine the impact of miR-1285-3p and miR-136-5p
on the expression of HERC4, we used miRNA mimics to
demonstrate that the expression levels of these two miRNAs
were inversely correlated with the expression levels of
HERC4, supporting the notion that these two miRNAs might
directly target HERC4 mRNA (Fig. 4B–D and Fig. S4C–D).
By mutating the predicted target sites of these miRNAs in the
3′ UTR of HERC4 mRNA, we confirmed that miR-1285-3p
and miR-136-5p regulated the levels of HERC4 mRNA by
targeting the predicted sites within the 3′ UTR of HERC4
(Figs. 4E and S4).
Since miR-1285-3p and miR-136-5p suppress HERC4
expression in breast cancer cells, we predicted that these
miRNAs could have the same tumor suppressive effects as
the silencing of HERC4. Consistent with this notion, the
induction of either miRNAs inhibited the proliferation,
migration and survival of breast cancer cells (Fig. 5), and the
inactivation of these miRNAs led to the opposite phenotypes
in tumorigenesis of breast cancer cells (Fig. S5). In addition,
the overexpression of miR-136-5p could suppress the
tumorigenesis induced by HERC4 overexpression
(Fig. S4E). Therefore, these data indicate that miR-1285-3p
and miR-136-5p could inhibit breast tumorigenesis by sup-
pressing the expression of HERC4.
DISCUSSION
Published and our data indicate that the HERC4 gene was
overexpressed in human breast cancers and its expression
predicts poor prognosis of breast cancer patients (Zhou
et al., 2013). However, the roles of HERC4 in tumorigenesis
remain unclear. LATS1 is a potent tumor suppressor, and the
inactivation or degradation of LATS1 promotes the devel-
opment of various human cancers, including breast cancer
(Britschgi et al., 2017). We discovered that HERC4 is a new
E3 ligase of LATS1 and can destabilize LATS1 in both nor-
mal breast epithelial cells and breast cancer cells by induc-
ing the ubiquitination of LATS1. In this context, we
demonstrate that the silencing of the HERC4 gene sup-
presses breast tumorigenesis and the overexpression of
HERC4 promotes breast tumorigenesis. Therefore, HERC4-
mediated degradation of LATS1 could represent a major
oncogenic pathway in breast cancer. Since HERC4 and
LATS1 genes are ubiquitously expressed, our findings sug-
gest that HERC4 could have broad oncogenic activity in
various human cancers. In support of this notion, the pub-
lished pathological studies have indicated that HERC4 is
associated with several types of malignant cancers such as
lung cancer and hepatic cancer (Zeng et al., 2015; Zheng
et al., 2017). In addition, our data also indicate that HERC4
promotes the tumorigenesis of human lung cancer cells.
Considering the important roles of HERC4 in tumorigen-
esis, we also investigated the upstream regulators of HERC4
in breast cancers and have identified two miRNAs that
suppress the expression of HERC4. Published and our data
indicate that both miR-1285-3p and miR-136-5p are down-
regulated in human breast cancers and other types of human
cancers (Liu et al., 2015; Li et al., 2017), suggesting that
these miRNAs are involved in tumor suppression. We show
that the expression of these miRNA is positively correlated
with the good prognosis of human breast cancer patients. In
further support of this notion, we demonstrate that both
miRNAs inhibit breast tumorigenesis by suppressing HERC4
expression. There is limited information on the pathways
regulating the expression of miR-1285-3p and miR-136-5p.
Therefore, it will be important to identify upstream tumor
suppressive pathways that activate the expression of these
miRNAs. Our discovery of the functional link between miR-
NAs, HERC4 and LATS1 reveals a pathway that plays
important roles in human breast tumorigenesis and provides
new therapeutic targets for breast cancer treatment.
MATERIALS AND METHODS
Human cancer cell lines and cell culture
Human normal mammary epithelial cell line (MCF-10A) and human
breast cancer cell lines (MDA-MB-231, MCF-7, T-47D, SK-BR-3 and
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BT-474) were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were cultured in Roswell
Park Memorial Institute 1640 medium (Gibco, USA) supplemented
with 10% fetal bovine serum (FBS, HyColne, Utah, USA) and 1%
penicillin/streptomycin (Thermo). HEK293T cells were obtained from
ATCC and cultured in DMEM (Gibco) supplemented with 10% FBS
and 1% penicillin-streptomycin.
Establishment of transfected cell lines
The vector expressing HERC4-specific siRNAs (HERC4-si-1:
CCUUUGGGCAGCUAGGUUU, HERC4-si-2: GGAUGUGGACU-
CAGACAUA, HERC4-si-3: GAUGGAACAGUGUACACAU) and
vector expressing human HERC4 cDNA were transfected into MCF-
7 and MCF-10A cells as previously described (Kim et al., 2015). The
cells were selected with puromycin (2 μg/mL, GeneChem) for three
days for stable transfectants.
Western blot analysis
Western blot was performed as previously described (Kim et al.,
2017), using anti-HERC4 antibody (ab85732, Abcam, Cambridge,
MA, USA), anti-LATS1 antibody (ab70561, Abcam), anti-HA poly-
clonal antibody (#71-5500, Thermo Fisher), anti-β-actin antibody
(ab8227, Abcam), and anti-GAPDH monoclonal antibody (ab9485,
Abcam). The levels of GAPDH and β-actin were used as loading
controls.
Cell proliferation and apoptosis assay
Cells transfected with various plasmids were seeded onto 96-well
plate (Corning Inc, Corning, NY, USA) at a density of 1 × 104 cells/
well in 96-well plates. At different time points (0 h, 24 h, 48 h and 72
h) after plating, the number of cells was assessed using cell counting
kit 8 according to the manufacturer’s protocol (Dojindo, Tokyo,
Japan). The transfected cell lines undergoing apoptosis were dis-
tinguished from live and necrotic cells by using Annexin-V and
Propidium iodide (PI) staining Kit (Calbiochem, San Diego, CA,
USA) as previously described (Zhang et al., 2014). All experiments
were independently repeated for three times.
Cell migration and invasion assay
For cell invasion assay, 1.5 × 105 cells in serum-free 1640 medium
were seeded into a matrigel coated chamber (8 μm pore size;
Corning Incorporated, NY, USA) and the lower chamber was
immediately filled with 500 μL of 1640 medium with 10 % FBS as a
chemoattractant. After 24 h of incubation, the non-invading cells
were removed from the upper chamber by a cotton swab, and the
membranes fixed with methanol and stained by 0.1 % crystal violet.
The data are represented as mean ± standard deviation (s.d.), n = 3.
Human cancer cell xenograft model
Five million human breast cancer cells were implanted into the
skeletal muscle of the hind limbs of 3–4 week-old BALB/c nude mice
(nu/nu) as previously described (Rong et al., 2014). Two weeks after
transplantation, the tumors were recovered and weighted. All animal
experiments were approved by the Institutional Animal Care and
Use Committee.
Dual-luciferase reporter assay
Cells were seeded in triplicate onto 6-well plates at a density of 4 ×
105 cells/well for two days. Cells were transfected with 0.3 μg of
REPOTM-AP-1-luc plasmid, or the control-luciferase plasmid,
together with 30 ng of pGMR TK renilla plasmid (GenomeDitech,
Shanghai, China) using LipofectamineTM 3000 reagent (Invitrogen,
Carlsbad, USA). Forty-eight hs after transfection, luciferase and
renilla activities were measured using the Dual Luciferase Reporter
Assay Kit (Promega, Madison, USA).
Protein stability analysis
Four hs after the transfection of the HERC4-specific siRNAs, cancer
cells were incubated with CHX (1:1000) and harvested at various
time points (0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h and 12 h) after transfections.
The levels of various proteins were determined by Western blot
analysis and quantified with ImageJ software.
Immunoprecipitation analysis
Immunoprecipitation assays were performed as previously descri-
bed (Kim et al., 2015). Briefly, cells were lysed in RIPA buffer con-
taining protease and phosphatase inhibitors, and cell extracts
collected after centrifugation. After being pre-cleared with 50 µL
protein A + G agarose, the cell extracts were immunoprecipitated
with 2 µg of the indicated antibodies and 50 µL protein G-agarose
overnight at 4 °C. The immune complexes were washed three times
with PBS buffer, re-suspended in SDS-PAGE sample buffer, and
analyzed by Western blot analysis.
Ubiquitination analysis
Protein ubiquitination was analyzed as previously described (Kim
et al., 2017). Thirty-six hs after the transfection of HA tagged ubiq-
uitin into HEK293Tcells, the cells were treated with 5 μmol/L MG132
overnight and harvested for cell extract. The cell extract was
immunoprecipitated with anti-HA antibody-conjugated agarose
beads. The levels of ubiquitination in the immunoprecipitate were
analyzed by Western blot analysis.
GST pull down assay
The primer sequences to clone different parts of LATS1 cDNA: 1–
1,500 bp, LATS1-Δ1-F-GTCGACATGAAGAGGAGTGAAAAGCC,
LATS1-Δ1-R-CTCGAGTTAACTTTTCACAGGCTGTTGAATAG; 1,501–
2,100 bp, LATS1-Δ2-F-GTCGACATGCGTGTATTAAAACCAGAGC,
LATS1-Δ2-R-CTCGAGTTACATTTTAGCCCTTTTAAGACG; 2,101–
3,393 bp, LATS1-Δ3-F-GTCGACATGGACAAGTCTATGTTTGTG,
LATS1-Δ3-R-CTCGAGTTAAACATATACTAGATCGCG.
The cDNAs of LATS1 were cloned into the GST expression
vector pET-22b (+). MCF-7 cells were transfected with vectors
expressing HERC4 and GST-LATS1 deletion mutants. Site-directed
mutagenesis was conducted according to the MutanBEST Kit
(R401, TaKaRa). GST beads, bait protein, prey protein were pre-
pared according to the Pierce™ GST Protein Interaction Pull-Down
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Kit (21516, Thermo Fisher). Apply bottom cap and remove top cap
on the pierce spin column containing the immobilized GST-tagged
bait protein. Up to 800 µL of prepared prey protein sample was
incubated at 4 °C for at least 1 h, centrifuged at 1,250 ×g for 30 s and
1,250 ×g for 30 s. Add 250 µL of the elution buffer to the spin
column. After the gentle rocking of the spin column on a rotating
platform for 5 min, the spin column was centrifuged at 1,250 ×g for 1
min. The levels of protein in the immunoprecipitate were analyzed by
Western blot analysis.
Statistical analysis
Data were analyzed using SPSS 20.0 or two-tailed independent
Student’s t-test. P < 0.05 was considered significant. The two patient
cohorts were compared by a Kaplan-Meier survival plot, and the log
rank P values are calculated.
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